相关实验视频

Updated: Jul 7, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

脑电图异常与抗抑郁药治疗结果不佳无关 - - 一项NeuroPharm研究

Kristian H Reveles Jensen¹, Olalla Urdanibia-Centelles², Vibeke H Dam³

¹Neurobiology Research Unit, Rigshospitalet, Copenhagen, Denmark; Department of Psychiatry, Psychiatric Centre Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology

|December 21, 2023

概括

大型抑郁症 (MDD) 患者的脑电图 (EEG) 异常与抗抑郁药治疗不响应无关. 然而,异常的脑电图活动与治疗前情绪和口头记忆差异相关.

科学领域:

神经科学是一个神经科学.
精神病学是一个精神病学.
临床神经生理学临床神经生理学

背景情况:

之前的研究表明,脑电图 (EEG) 异常,包括缓慢和孤立的发性放电 (IED),预测了对抗抑郁药物 (如埃斯基塔洛普拉姆和文拉法辛) 的不反应.
这意味着在治疗一些患有严重抑郁症 (MDD) 的患者时,可能需要抗药物.

研究的目的:

在MDD患者中复制EEG异常和抗抑郁药治疗结果之间的关联.
探索治疗期间EEG发现,情绪和认知功能之间的关系.

主要方法:

一项涉及91名MDD患者 (18-57岁) 的开放性试验,他们接受了12周的埃斯基塔洛普拉姆 (10-20毫克) 治疗.
在治疗前的静止状态256通道EEG被认证的临床神经生理学家分析.
患者可以在四周后切换到杜洛西丁;响应和缓解率在8周和12周被评估.

主要成果:

在19.8%的患者中存在EEG异常 (减速,IED或含义不明).
在患有EEG异常和没有EEG异常的患者之间,没有观察到缓解或响应率的显著群体差异.
脑电图异常的患者在治疗前表现出更高的愤怒和更差的口头记忆.

结论:

该研究没有证实EEG异常作为MDD中埃斯基塔洛普拉姆不响应的预测因素.
异常的EEG活动与较差的基线情绪和口头记忆有关,但与治疗诱导的改善无关.
需要进一步评估以确定EEG异常在指导抗抑郁药物选择中的临床有用性.

关键词:

这是一个EEGEEGEEGEEGEEGEEGEEG.埃斯基塔洛普拉姆 (escitalopram) 是一种药物.大型抑郁症主要是抑郁症.这是一个SSRI.语言记忆语言记忆

更多相关视频

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD

Published on: March 12, 2020

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

相关概念视频

Electroconvulsive Therapy

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...

Antidepressant Drugs: MAOIs and Other Agents

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...